Home / Mumbai / Mumbai News / Article / Mumbai: Haffkine Bio-Pharma hopeful of Covaxin production in 8 months, targets 22.8 crore doses a year

Mumbai: Haffkine Bio-Pharma hopeful of Covaxin production in 8 months, targets 22.8 crore doses a year

The Department of Biotechnology has given permission to HBPCL for producing Covaxin under Mission Covid Suraksha. Covaxin has been developed by Bharat Biotech in collaboration with ICMR.

Listen to this article :
A health worker prepares to inoculate a woman with a dose of the Covaxin Covid-19 vaccine. Pic/AFP

A health worker prepares to inoculate a woman with a dose of the Covaxin Covid-19 vaccine. Pic/AFP

Haffkine Bio-Pharmaceutical Corporation Limited (HBPCL), a Maharashtra government undertaking, is preparing for mass production of Covaxin and will have capacity to produce over 22 crore doses of the Covid-19 vaccine every year once the requisite facilities are in place.

The Department of Biotechnology has given permission to HBPCL for producing Covaxin under Mission Covid Suraksha. Covaxin has been developed by Bharat Biotech in collaboration with ICMR. Sandeep Rathod, Managing Director of HBPCL, told ANI that formalities of technology transfer from Bharat Biotech are being completed.

How do you like the new new mid-day.com experience? Share your feedback and help us improve.

Read Next Story
Mumbai: 9 bidders shortlisted for redevelopment of Chhatrapati Shivaji Maharaj Terminus

Trending Stories

Latest Photoscta-pos

Latest VideosView All

Latest Web StoriesView All

Mid-Day FastView All

Advertisement